FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3198589062> ?p ?o ?g. }

• W3198589062 abstract "Abstract Background: A feedforward pathological signaling loop generated by TNFα and IFN-γ synergy in the inflamed lung, driving CXCL-10 (IP-10) and CXCL-9 chemokine-mediated activated T-cell and monocyte/macrophage tissue recruitment, may define the inflammatory biology of lethal COVID-19 respiratory failure. Methods: To assess TNFα-antagonist therapy, 18 hospitalized adults with hypoxic respiratory failure and COVID-19 pneumonia received single-dose infliximab-abda therapy 5 mg/kg intravenously between April and December 2020. The primary endpoint was time to increase in oxygen saturation to fraction of inspired oxygen ratio (SpO2/FiO2) by ≥50 compared to baseline and sustained for 48 h. Secondary endpoints included 28-day mortality, dynamic cytokine profiles, secondary infections, duration of supplemental oxygen support, and hospitalization. Findings: Patients were predominantly in critical respiratory failure (15/18, 83%), male (14/18, 78%), above 60 years (median 63 years, range 31–80), race-ethnic minorities (13/18, 72%), lymphopenic (13/18, 72%), steroid-treated (17/18, 94%), with a median ferritin of 1953 ng/ml. Sixteen patients (89%) met the primary endpoint within a median of 4 days; 14/18 (78%) were discharged in a median of 8 days and were alive at 28-day follow-up. Three deaths were attributed to secondary lung infection. Mean plasma IP-10 levels declined sharply from 9183 to 483 pg/ml at Day 3 and 146 pg/ml at Day 14/discharge. Significant Day 3 declines in IFN- $gamma $ , TNFα, IL-27, CRP, and ferritin occurred. IP-10 and CXCL-9 declines were strongly correlated among patients with lymphopenia reversal (Day 3, Pearson r : 0.98, P -value 0.0006). Interpretation: Infliximab-abda may rapidly abrogate pathological inflammatory signaling to facilitate clinical recovery in severe and critical COVID-19." @default.
• W3198589062 created "2021-09-13" @default.
• W3198589062 creator A5008387402 @default.
• W3198589062 creator A5015443341 @default.
• W3198589062 creator A5017249023 @default.
• W3198589062 creator A5021874324 @default.
• W3198589062 creator A5022979104 @default.
• W3198589062 creator A5024664062 @default.
• W3198589062 creator A5027947297 @default.
• W3198589062 creator A5055111142 @default.
• W3198589062 creator A5055169462 @default.
• W3198589062 creator A5062249687 @default.
• W3198589062 creator A5063763615 @default.
• W3198589062 creator A5074401925 @default.
• W3198589062 date "2021-01-01" @default.
• W3198589062 modified "2023-09-30" @default.
• W3198589062 title "Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNFα-antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure" @default.
• W3198589062 cites W1603392814 @default.
• W3198589062 cites W1607601839 @default.
• W3198589062 cites W1963758164 @default.
• W3198589062 cites W1978082123 @default.
• W3198589062 cites W1988157428 @default.
• W3198589062 cites W1997834526 @default.
• W3198589062 cites W2018750367 @default.
• W3198589062 cites W2025556668 @default.
• W3198589062 cites W2050609154 @default.
• W3198589062 cites W2076753860 @default.
• W3198589062 cites W2094736478 @default.
• W3198589062 cites W2149862868 @default.
• W3198589062 cites W2169854416 @default.
• W3198589062 cites W2170928419 @default.
• W3198589062 cites W2285232686 @default.
• W3198589062 cites W2336487821 @default.
• W3198589062 cites W2570098856 @default.
• W3198589062 cites W2588847707 @default.
• W3198589062 cites W2783849477 @default.
• W3198589062 cites W2995551822 @default.
• W3198589062 cites W3000124921 @default.
• W3198589062 cites W3001118548 @default.
• W3198589062 cites W3015861468 @default.
• W3198589062 cites W3021841162 @default.
• W3198589062 cites W3023991776 @default.
• W3198589062 cites W3032543466 @default.
• W3198589062 cites W3036155640 @default.
• W3198589062 cites W3036214010 @default.
• W3198589062 cites W3037676127 @default.
• W3198589062 cites W3049325061 @default.
• W3198589062 cites W3080081523 @default.
• W3198589062 cites W3080981445 @default.
• W3198589062 cites W3089589823 @default.
• W3198589062 cites W3093693178 @default.
• W3198589062 cites W3095138575 @default.
• W3198589062 cites W3097316698 @default.
• W3198589062 cites W3097465023 @default.
• W3198589062 cites W3105908160 @default.
• W3198589062 cites W3112984291 @default.
• W3198589062 cites W3120469415 @default.
• W3198589062 cites W3120857229 @default.
• W3198589062 cites W3134674969 @default.
• W3198589062 cites W3138901698 @default.
• W3198589062 cites W3154642949 @default.
• W3198589062 cites W3160595368 @default.
• W3198589062 cites W4210642183 @default.
• W3198589062 doi "https://doi.org/10.1017/cts.2021.805" @default.
• W3198589062 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8376916" @default.
• W3198589062 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34457357" @default.
• W3198589062 hasPublicationYear "2021" @default.
• W3198589062 type Work @default.
• W3198589062 sameAs 3198589062 @default.
• W3198589062 citedByCount "25" @default.
• W3198589062 countsByYear W31985890622021 @default.
• W3198589062 countsByYear W31985890622022 @default.
• W3198589062 countsByYear W31985890622023 @default.
• W3198589062 crossrefType "journal-article" @default.
• W3198589062 hasAuthorship W3198589062A5008387402 @default.
• W3198589062 hasAuthorship W3198589062A5015443341 @default.
• W3198589062 hasAuthorship W3198589062A5017249023 @default.
• W3198589062 hasAuthorship W3198589062A5021874324 @default.
• W3198589062 hasAuthorship W3198589062A5022979104 @default.
• W3198589062 hasAuthorship W3198589062A5024664062 @default.
• W3198589062 hasAuthorship W3198589062A5027947297 @default.
• W3198589062 hasAuthorship W3198589062A5055111142 @default.
• W3198589062 hasAuthorship W3198589062A5055169462 @default.
• W3198589062 hasAuthorship W3198589062A5062249687 @default.
• W3198589062 hasAuthorship W3198589062A5063763615 @default.
• W3198589062 hasAuthorship W3198589062A5074401925 @default.
• W3198589062 hasBestOaLocation W31985890621 @default.
• W3198589062 hasConcept C126322002 @default.
• W3198589062 hasConcept C168563851 @default.
• W3198589062 hasConcept C203014093 @default.
• W3198589062 hasConcept C203092338 @default.
• W3198589062 hasConcept C2776888751 @default.
• W3198589062 hasConcept C2777914695 @default.
• W3198589062 hasConcept C2778319317 @default.
• W3198589062 hasConcept C71924100 @default.
• W3198589062 hasConcept C90924648 @default.
• W3198589062 hasConceptScore W3198589062C126322002 @default.
• W3198589062 hasConceptScore W3198589062C168563851 @default.
• W3198589062 hasConceptScore W3198589062C203014093 @default.
• W3198589062 hasConceptScore W3198589062C203092338 @default.

• next